Aquestive Therapeutics

Patent Extensions and FDA Momentum Will Support Upcoming Needle-Free Epinephrine Launch

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

31 Mar 25

Updated

07 Dec 25

Views

314

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

62.7%

7D

-9.6%

Loading

1Y

62.7%

7D

-9.6%

You can edit this narrative until Dec 8 4:05 PM. Then, changes will post as Updates.

Author's Valuation

US$10.345.3% undervalued

AnalystConsensusTarget Fair Value

Shared on 07 Dec 25

AQST: Extended Patent Protection Will Support Future Share Price Outperformance

Analysts nudged their price targets on Aquestive Therapeutics higher by roughly $3 to $12, citing newly issued patents that extend Anaphylm's exclusivity through at least 2037 and growing confidence in FDA approval prospects following the decision not to convene an advisory committee for the NDA. Analyst Commentary Street research has turned increasingly constructive on Aquestive Therapeutics as recent developments around Anaphylm have prompted upward revisions to valuation models and a reassessment of execution risk.

Shared on 23 Nov 25

Fair value Increased 13%

AQST: Multiple Patent Wins And Regulatory Progress Will Support Continued Share Price Outperformance

Analysts have raised their fair value estimate for Aquestive Therapeutics from $9.08 to $10.30. This change reflects recent patent wins for Anaphylm and improved regulatory outlooks, which are expected to enhance long-term growth and exclusivity for the company.

Shared on 07 Nov 25

AQST: Extended Patent Protection Will Drive Sustained Share Price Upside

Analysts have recently raised their price targets for Aquestive Therapeutics, with notable increases from $7 to $8 and from $9 to $12. They cite strengthened patent protection for Anaphylm and a smoother regulatory pathway as key drivers behind their more optimistic outlook.

Shared on 24 Oct 25

Analysts have recently raised their price targets for Aquestive Therapeutics, with increases up to $12 per share. They cite extended patent protection for Anaphylm and positive regulatory developments as key factors supporting a more optimistic outlook.

Shared on 09 Oct 25

Fair value Increased 5.83%

The analyst fair value estimate for Aquestive Therapeutics has been increased by $0.50 to $9.08. Analysts cite recent patent extensions and regulatory progress for Anaphylm as key drivers of the upward revision.

Shared on 01 May 25

Fair value Decreased 2.89%

Shared on 24 Apr 25

Fair value Decreased 4.44%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.1%.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Increased 9.78%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

AnalystConsensusTarget Fair Value

US$10.3

45.3% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

36.76%

Pharma revenue growth rate

0.68%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

6.96%

Calculation

US$13.32m

Earnings '28

x

216.94x

PE Ratio '28

=

US$2.89b

Market Cap '28

US$2.89b

Market Cap '28

/

229.23m

No. shares '28

=

US$12.60

Share Price '28

US$12.60 Share Price '28

Discounted to 2025 @ 6.96% p.a.

=

US$10.30

Fair Value '25